Home・Elenco Azioni・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Chiusa

SettoreSettore sanitario

3.34 1.83

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.2800000000000002

Massimo

3.39

Metriche Chiave
By Trading Economics
Entrata	4.1M -5.7M
EPS	-0.06
Dipendenti	34
EBITDA	-821K -6.5M

Dividendi
By Acuity
Utili prossimi	11 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	42M 273M
Apertura precedente	1.51
Chiusura precedente	3.34

Notizie sul Sentiment di mercato

By Acuity

86%

14%

321 / 340 Classifica in Healthcare

Anavex Life Sciences Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 ago 2026, 22:16 UTC

Anavex Life Sciences Corp is higher in after-market trading, continuing a trend of gains over the last seven sessions, despite no specific news identified.

6 ago 2026, 23:51 UTC

Anavex Life Sciences Corp is rising in after-market trading, reaching a high shortly after the market closed, despite no specific news driving the increase.

5 ago 2026, 21:01 UTC

Anavex Life Sciences shares fell in after-market trading, declining significantly despite being above its 20-day moving average and near the top of its one-month range.

4 ago 2026, 19:51 UTC

Anavex Life Sciences Corp is rising amid broader market strength and a decline in crude oil prices, despite pulling back from earlier session highs.

3 ago 2026, 20:02 UTC

News

Anavex Life Sciences Corp announces board changes amid a proxy fight, urging stockholders to reject PVG Asset Management's attempt to replace the board. Shares are higher.

30 lug 2026, 19:39 UTC

Event

Anavex Life Sciences reported Q2 earnings of -$0.06 per share, beating expectations. Shares remain higher since Wednesday's close despite pulling back from session highs.

29 lug 2026, 22:31 UTC

Anavex Life Sciences Corp shares are higher in after-market trading, reflecting broader market gains following the Federal Reserve's decision to maintain interest rates.

28 lug 2026, 21:01 UTC

Anavex Life Sciences Corp shares are lower in after-market hours, currently 1.45% below their 20-day moving average. No specific news was identified.

27 lug 2026, 20:07 UTC

Anavex Life Sciences Corp shares are higher during Monday's session, maintaining gains since Friday amid broader market trends and easing geopolitical tensions.

24 lug 2026, 17:46 UTC

Anavex Life Sciences Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the move.

21 lug 2026, 19:51 UTC

Anavex Life Sciences is rising during Tuesday's session, recovering from a pre-market low. Broader market sentiment is supported by positive earnings from General Motors and Novartis.

Confronto tra pari

Modifica del prezzo

Anavex Life Sciences Corp Previsione

Consenso sulla valutazione

By TipRanks

0 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 0 che hanno fornito valutazioni azionarie a Anavex Life Sciences Corp - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

321 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.